Webinar: The Emerging Influence of Digital Biomarkers on Healthcare
Digital biomarkers, omics technologies and behavioural interventions have a huge potential to improve treatment outcome for patients, but challenges around evidence generation, infrastructure, incentives, and workflow remain. Sign up and get in-depth knowledge of the potential and the challenges.
Start: 18.12.2020 | at 9:30 AM
End: 18.12.2020 | at 11:00 AM
Download the presentations
We have invited speakers from three organisations, and you will get three very different perspectives on digital biomarkers. Digital biomarkers are defined as objective, quantifiable physiological and behavioural data that are collected and measured by means of digital devices such as portables, wearables, implantables or digestibles. The data collected is typically used to explain, influence and predict health-related outcomes.
Meet and learn from some of the most important Danish organisations
Danish National Genome Center supports development of personalised medicine in Denmark with new treatments through the use of knowledge and new technologies. The Center is a new government agency and an authority within the Danish Healthcare system. The Center’s primary task is to lay the foundation for the development of better diagnostics and more targeted treatments for patients using whole-genome sequencing (WGS).
University of Southern Denmark where the second speakers have done most of his research. Anton Pottegård’s research interest lies within the use of drugs in the broadest sense. Mostly, his research takes its point of departure in Danish or international health registry data, where he seeks to describe both known and unknown side effects of treatment with drugs.
Omhu, a spin-out of LeoPharma. A company that strives to create a technology that will transform skin health. Artificial intelligence has the potential to dramatically augment the work of dermatologists and lead to new treatment paradigms for people with skin conditions. Understanding how and where technology can make the most impact is as much Omhu’s concern as developing the technology itself.
M.D., D.M.Sc. and CEO in Danish National Genome Center. Lundgren is a specialist in clinical microbiology and Doctor of Medical Science (D.M.Sc.) from the University of Copenhagen.
Bettina Lundgren leads the establishment of Danish National Genome Center with a strong focus on patient outcome and the promotion of international and national cooperation within research and across the Danish Health Care system.
M.D. and Senior Medical Advisor at Omhu, LEO innovation Lab.
Working at the intersection between tech and dermatology, making healthtech solutions for patients and doctors working with skin-diseases. Author of educational book in dermatology and a popular book discussion the future of healthcare and family medicine.
Clinical pharmacist, PhD, Professor of Clinical Pharmacy and Pharmacoepidemiology at Department of Public Health, University of Southern Denmark.
Analysing data on use patterns and effects of medicines to support the most rational use of drugs. Professor of pharmacoepidemiology and clinical pharmacy using real-world data from Danish or international data sources to investigate known or unknown effects of drug treatment.